Zacks flags Kimberly-Clark deal risks for Kenvue stock

Published on 10/02/2026 at 15:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kenvue sales rose 3.00 percent year over year in the June 28 quarter. Kenvue stock costs EUR 15.36 on October 2, 2026 versus EUR 15.48.

Isometrische 3D-Illustration einer Konsumgüter-Lieferkette mit Fabrik und Lager — Isometrisches 3D-Diagramm der Wertschöpfungskette illustriert Produktion und Vertrieb von Kenvue ISIN US49177J1025, Illustration mit AI erstellt.

Kenvue (ISIN US49177J1025) is facing deal-execution risks as its planned combination with Kimberly-Clark advances, while Kenvue stock was at EUR 15.36 at Lang & Schwarz on October 2, 2026. Zacks reported on September 7, 2026 that the cash-and-stock transaction remained subject to foreign regulatory approvals and customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

Deal timing meets operating pressure

The pending transaction has also changed Kenvue's financial communication. The company is not providing forward-looking guidance while the deal remains pending, leaving quarterly execution and closing conditions as the central near-term variables.

In the fiscal second quarter ended June 28, 2026, net sales increased 3.00 percent year over year to USD 3.955 billion, while organic sales grew 1.60 percent. Kenvue reported diluted earnings per share of USD 0.24, compared with USD 0.22 in the prior-year quarter, while adjusted earnings per share rose to USD 0.31 from USD 0.29.

Margins show the counterweight

The sales gain came with pressure on profitability. Adjusted gross margin declined to 60.20 percent from 60.90 percent in the second quarter of 2025, a 0.70 percentage-point reduction linked to inflation, tariffs and transactional currency effects.

The segment mix was uneven. Second-quarter Skin Health and Beauty sales increased 5.10 percent year over year, while Self Care sales increased 2.20 percent and organic Self Care sales rose 0.60 percent. That contrast matters because the company is entering a transaction period while still working through category-level differences in demand.

Stock remains below its yearly high

A separate NYSE quote showed KVUE at USD 17.35 at 9:51 a.m. ET on October 2, 2026, with a 52-week range of USD 14.02 to USD 20.13 and a market capitalization of USD 33.3 billion. The NYSE listing and KVUE ticker are identified by MarketBeat.

For investors, the numbers frame Kenvue as a transaction-dependent consumer health story rather than a simple growth case. Revenue growth and stronger Skin Health and Beauty performance provide operating support, but margin compression and the absence of forward guidance increase the importance of regulatory clearance and execution through the planned closing window.

At Lang & Schwarz, Kenvue was trading at EUR 15.36 on October 2, 2026 at 3:38 p.m. CEST, down 0.78 percent versus the prior close of EUR 15.48. The further course of trading is shown by the continuously updated real-time quote of Kenvue stock.